Physician profile
Dan W Robinson
NPI 1447244777
$3,695.69
in general payments reported to CMS, 2019-2025
42 companies · $921 in 2025
The $921 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $697 · 2020: $174 · 2021: $223 · 2022: $260 · 2023: $531 · 2024: $891 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,342.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $455.43 | 2022-2025 | Vyepti, Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $291.24 | 2019-2025 | Xifaxan |
| Novo Nordisk INC | $247.51 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $245.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $241.26 | 2019-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $231.92 | 2019-2025 | Jardiance, Mounjaro, Kisunla |
| Abbvie INC. | $162.43 | 2023-2025 | Vraylar |
| Pfizer INC. | $138.25 | 2019-2025 | |
| Glaxosmithkline, LLC. | $133.21 | 2019-2024 | Shingrix, Trelegy Ellipta |
| Argenx US, INC. | $109.84 | 2024-2025 | Vyvgart Hytrulo |
| Organogenesis INC. | $108.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.96 | 2019-2023 | Tradjenta, Synjardy |
| Ucb, INC. | $105.02 | 2024-2025 | Rystiggo, Nayzilam, Fintepla |
| Merck Sharp & Dohme LLC | $89.77 | 2019-2021 | |
| Daiichi Sankyo INC. | $84.06 | 2024-2025 | Injectafer |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $78.28 | 2020-2025 | Evenity, Prolia, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $74.81 | 2019-2025 | Hyqvia |
| Otsuka America Pharmaceutical, INC. | $72.00 | 2023-2025 | Rexulti |
| Eisai INC. | $71.76 | 2024 | |
| Sanofi-Aventis U.S. LLC | $58.80 | 2019-2020 | |
| Astellas Pharma US INC | $57.29 | 2019 | |
| Emd Serono, INC. | $51.90 | 2024 | |
| Janssen Pharmaceuticals, INC | $50.75 | 2019-2020 | |
| Antares Pharma, INC. | $42.92 | 2019-2020 | |
| Abbott Laboratories | $36.06 | 2021-2025 | Freestyle Libre 3 |
| Allergan, INC. | $29.99 | 2019 | |
| Exact Sciences Corporation | $28.28 | 2023 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $27.03 | 2021 | |
| Abiomed | $24.88 | 2024 | Impella |
| Livanova USA, INC. | $23.77 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Csl Behring | $22.39 | 2025 | Hizentra |
| Ibsa Pharma INC. | $22.08 | 2023 | Tirosint, Licart |
| Vital Connect, INC | $21.63 | 2025 | Vitalpatch Rtm |
| Dexcom, INC. | $20.50 | 2025 | Dexcom G6 Transmitter |
| Acadia Pharmaceuticals INC | $19.80 | 2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $18.42 | 2024 | Ultomiris |
| Biohaven Pharmaceuticals, INC. | $18.17 | 2021 | |
| Mylan Specialty L.P. | $16.33 | 2020 | |
| Boston Scientific Corporation | $15.83 | 2023 | Watchman Access System |
| Shire North American Group INC | $14.50 | 2019 | |
| C2n Diagnostics, LLC | $14.25 | 2025 | Precivityad2 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.76 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.